<DOC>
	<DOCNO>NCT01854489</DOCNO>
	<brief_summary>This study aim examine possible interaction sublingual intravenous buprenorphine rifampicin .</brief_summary>
	<brief_title>Effects Rifampicin Pharmacokinetics Pharmacodynamics Sublingual Intravenous Buprenorphine</brief_title>
	<detailed_description>Variability drug response due either pharmacokinetic pharmacodynamic factor . The reason people differ pharmacokinetics pharmacodynamics manifold include , e.g. , genetic factor , disease , age concomitantly administer drug . Oxidation reaction dominant metabolism drug cytochrome P-450 enzyme ( CYP ) recognize chief contributor . We previously show drug interaction mediate inhibition CYP enzymes may major clinical significance.Buprenorphine semisynthetic partial µ-opioid receptor agonist . In low dos , use treatment moderate acute chronic pain whereas high dos , use management opioid withdrawal symptom opioid addiction . It high affinity µ-opioid receptor analgesic efficacy 20-40 time morphine . It act antagonist myy-opioid receptor agonist myy-opioid receptor opioid-like receptor ( ORL-1 ) . Buprenorphine undergoes extensive first-pass metabolism low oral bioavailability 15 % . Bioavailability follow sublingual administration buprenorphine high , 50-60 % . After high sublingual dos buprenorphine ( 8-24 mg ) , peak plasma concentration reach 1 hour low sublingual dos ( 0.4 mg ) reach approximately 3 h. Approximately two-thirds buprenorphine dose excrete unchanged , rest metabolize liver intestinal wall . N-dealkylation buprenorphine mainly via CYP3A also CYP2C8 yield norbuprenorphine , glucuronidation yield buprenorphine-3-glucuronide . Norbuprenorphine excrete urine subsequent conjugation . 80-90 % buprenorphine excrete biliary system enterohepatic circulation.Although interaction study high-dose buprenorphine antiretrovirals conduct , effect CYP3A inducer pharmacokinetics low-dose buprenorphine unknown . Because use buprenorphine pain management increase introduction transdermal buprenorphin patch market , clinically relevant study quantify possible interaction buprenorphine inducer CYP3A-mediated metabolism rifampicin .</detailed_description>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>nonsmoking age 1840 year body weight within ±15 % ideal weight height Exclusion Criteria A previous history intolerance study drug related compound additive . Concomitant drug therapy kind least 14 day prior study . Subjects young 18 year old 40 year . Existing recent significant disease . History hematological , endocrine , metabolic gastrointestinal disease , include gut motility disorder . History asthma kind drug allergy . Previous present alcoholism , drug abuse , psychological emotional problem likely invalidate inform consent , limit ability subject comply protocol requirement . A positive test result urine toxicology . A `` yes '' answer one Abuse Questions . Pregnancy nursing . Donation blood 4 week prior study . Special diet life style condition would compromise condition study interpretation result . Participation study involve investigational market drug product concomitantly within one month prior entry study . Smoking one month start study whole study period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Buprenorphine</keyword>
	<keyword>Rifampicin</keyword>
	<keyword>Interactions</keyword>
	<keyword>Pharmakokinetics</keyword>
	<keyword>Pharmakodynamics</keyword>
</DOC>